iCAD, Inc. (NASDAQ:ICAD) Shares Sold by NewEdge Advisors LLC

NewEdge Advisors LLC lowered its stake in iCAD, Inc. (NASDAQ:ICAD - Free Report) by 59.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 56,308 shares of the technology company's stock after selling 81,886 shares during the period. NewEdge Advisors LLC owned 0.21% of iCAD worth $103,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Summit Trail Advisors LLC bought a new stake in iCAD in the fourth quarter valued at about $214,000. Geode Capital Management LLC grew its position in shares of iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock worth $506,000 after acquiring an additional 17,059 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of iCAD by 6.1% in the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company's stock valued at $1,311,000 after acquiring an additional 41,000 shares during the last quarter. Thompson Davis & CO. Inc. acquired a new stake in shares of iCAD during the 4th quarter valued at approximately $31,000. Finally, waypoint wealth counsel lifted its stake in iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock worth $26,000 after purchasing an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 24.61% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ICAD. Craig Hallum cut shares of iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. BTIG Research cut shares of iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. StockNews.com started coverage on iCAD in a research note on Sunday. They issued a "sell" rating for the company. Finally, Laidlaw reiterated a "hold" rating on shares of iCAD in a research report on Thursday, April 17th.

iCAD Stock Performance

Shares of iCAD stock traded up $0.10 during trading on Thursday, hitting $3.70. 116,017 shares of the stock were exchanged, compared to its average volume of 386,261. The stock has a market cap of $101.55 million, a PE ratio of -28.46 and a beta of 1.35. The stock's fifty day moving average is $2.47 and its 200 day moving average is $2.29. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78.

iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.02. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The company had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.